期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

RASA1在胰腺癌中的异常表达及其临床意义 被引量：5

Abnormal expression and clinical significance of RASA1 in pancreatic carcinoma
下载PDF
导出
摘要 目的:探讨Ras p21蛋白活化子1(Ras p21 protein activator 1,RASA1)在胰腺癌中的表达状况及可能作用。方法:以qRT-PCR检测胰腺癌细胞(Capan-2、CFPAC-1、BxPC-3)和胰腺导管上皮细胞(H6C7)中RASA1 mRNA表达水平的差异,以Western blotting检测上述细胞之间RASA1蛋白表达水平的差异;以免疫组化检测RASA1蛋白在胰腺癌及胰腺良性病变(慢性胰腺炎、胰腺囊肿)中的表达差异,并观察其表达水平与胰腺癌各临床病理因素之间的联系。结果:各胰腺癌细胞株中RASA1 mRNA和蛋白表达水平均低于胰腺导管上皮细胞(P<0.05)。肿瘤组织RASA1蛋白表达水平显著低于良性病变组织(P<0.05);侵犯周边器官的肿瘤组织中RASA1表达显著低于局限于胰腺内的组织(P<0.05);Ⅰ期胰腺癌组织RASA1的表达则显著高于Ⅱ、Ⅲ期的癌组织(P<0.05);但RASA1表达与胰腺癌的远处转移关系尚不明确。结论:RASA1作为抑癌蛋白可能在胰腺癌的发生发展中发挥重要作用。 AIM： To investigate the role of Ras p21 protein activator 1 （RASA1） in the development and progress of pancreatic cancer. METHODS： Different expression levels of RASA1 were measured by qRT-PCR and Western blotting in the pancreatic cancer cells Capan-2, CFPAC-1 and BxPC-3, and the pancreatic ductal cell line H6C7. Besides, the different expression levels between the pancreatic cancer and the pancreatic benign lesions, such as chronic pancreatitis or pancreatic cyst, were detected by the method of immunohistochemistry. The relationship between the clinicopathological feature and the RASA1 expression was analyzed. RESULTS： Both mRNA and protein expression levels of RASA1 decreased in pancreatic cancer cells compared with the ones in the pancreatic ductal cells （P〈0.05）. The protein level of RASA1 in the pancreatic cancer tissues was lower than that in the pancreatic benign lesion tissues （P〈0.05）. The pancreatic cancer samples with adjacent organ invasion had a significantly lower expression level of RASA1 than that in the pancreatic cancer samples limited in the pancreas （P〈0.05）. The expression levels of RASA1 were much higher in the cancers on stage I than the ones on stage II or Ⅲ （P〈0.05）. However, no relationship between the RASA1 expression level and the maximum diameter of cancer, the lymph node invasion and the survival time was observed. CONCLUSION： RASA1 plays an important role in the pancreatic cancer development as a potential tumor suppressor.
作者 秦玉璇 李东风 张世能 段伊帆 谢子钧 李子俊
机构地区 南方医科大学研究生院 广东省医学科学院 广东省医学科学院 中山大学孙逸仙纪念医院消化科
出处 《中国病理生理杂志》 CAS CSCD 北大核心 2012年第6期991-995,共5页 Chinese Journal of Pathophysiology
基金 广东省科技计划(No.2010B050700014 No.2011B0318000004)
关键词 RASA1蛋白 人 癌基因蛋白质K-Ras 胰腺肿瘤 RASA1 protein, human Oncogene protein K - Ras Pancreatic neoplasms
分类号 R735.9 [医药卫生—肿瘤]
  • 相关文献

参考文献13

  • 1顾凯,吴春晓,鲍萍萍,王春芳,彭鹏,龚杨明,向詠梅,黄哲宙,金凡,郑莹,卢伟.上海市胰腺癌流行现况、回顾与比较分析[J].外科理论与实践,2009,14(5):510-515. 被引量：54
  • 2Siegel R,Ward E,Brawley O. Cancer statistics,2011:the impact of eliminating socioeconomic and racial disparities on premature cancer deaths[J].CA:A Cancer Journal for Clinicians,2011,(04):212-236.
  • 3Jones S,Zhang X,Parsons DW. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses[J].Science,2008,(5897):1801-1806.
  • 4吴文辉,肖隆斌,汤友珍,蔡世荣,詹文华.K-ras基因突变与结直肠癌生物学行为的关系[J].中国病理生理杂志,2009,25(11):2159-2162. 被引量：19
  • 5Ohta M,Seto M,Ijichi H. Decreased expression of the RAS-GTPase activating protein rasal1 is associated with colorectal tumor progression[J].Gastroenterology,2009,(01):206-216.
  • 6Calvisi DF,Ladu S,Conner EA. Inactivation of ras GTPase-activating proteins promotes unrestrained activity of wild-type ras in human liver cancer[J].Journal of Hepatology,2011,(02):311-319.
  • 7Marshall MS,Hill WS,Ng AS. A C-terminal domain of GAP is sufficient to stimulate ras p21 GTPase activity[J].EMBO Journal,1989,(04):1105-1110.
  • 8Iyengar P,Tsao MS. Clinical relevance of molecular markers in lung cancer[J].Surgical Oncology,2002,(04):167-179.
  • 9Davidson B,Agulansky L,Goldberg I. Immunohistochemical analysis of rasGTPase activating protein rasGAP in prostate cancer[J].Pathology Research and Practice,1998,(06):399-404.
  • 10Hu X,Stern HM,Ge L. Genetic alterations and oncogenic pathways associated with breast cancer subtypes[J].Molecular Cancer Research,2009,(04):511-522.

二级参考文献43

  • 1朱德斌,邢达,李贤,张岚.实时荧光等位基因特异性扩增法快速检测K-ras癌基因点突变[J].高等学校化学学报,2007,28(6):1031-1034. 被引量：3
  • 2J Ferlay, F Bray, P Pisani, et al. GLOBOCAN 2002: Cancer Incidence, Mortality and Prevalence Worldwide. IARC CancerBase No.5[CP/DK]. version 2.0. Lyon: IARC Press, 2004.
  • 3O'Sullivan A, Kocher HM. Pancreatic cancer[J]. Br Med J(Clin Evid), 2007,11:409-437.
  • 4Li D, Xie K, Wolff R, et al. Pancreatic cancer[J]. Lancet, 2004,363(9414): 1049-1057.
  • 5Parkin DM, Chen VW, Ferlay J, et al. Comparability and quality control in cancer registration. IARC Technical Report No 19[M]. Lyon: IARC Press, 1994.
  • 6Jensen OM, Parkin DM, MacLennan R, et al. Cancer registration: principles and methods [M]. Lyon: IARC Scientific Publications, 1991.
  • 7全国肿瘤防治研究办公室.中国肿瘤登记工作指导手册[M].北京:中国协和医科大学出版社,2006.
  • 8Esteve J, Benhamou E, Raymond L. Statistical methods in cancer research, Vol. iV-descriptive epidemiology[M]// IARC Sci Publ No.128. Lyon: IARC, 1994.
  • 9Michaud DS. Epidemiology of pancreatic cancer[J]. Minerva Chit, 2004,59(2):99-111.
  • 10Parkin DM, Whelan S, Ferlay J, et al. Cancer incidence in five continents, Vol. Ⅰ to Ⅷ. IARC CancerBase No.7 [CP/DK]. Lyon: IARC Press, 2005.

共引文献71

同被引文献33

  • 1Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015[J]. CA Cancer J Clin, 2016, 66(2): 115-132.
  • 2Kris MG, Johnson BE, Berry LD, et al. Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs [ J 1. JAMA, 2014, 311(19): 1998-2006.
  • 3Chan BA, Hughes BG. Targeted therapy for non-small cell lungcancer: current standards and the promise of the future [ J ]. Transl Lung Cancer Res, 2015, 4(1) : 36-54.
  • 4Miller MS, Miller LD. RAS Mutations and oncogenesis: Not all RAS mutations are created equally [ J]. Front Genet, 2012, 2 (100) : 1-9.
  • 5Calvisi DF, Ladu S, Conner EA, et al. Inactivation of Ras GT- Pase-activating proteins promotes unrestrained activity of wild- type Ras in human liver cancer [ J ]. J Hepatol, 2011, 54 (2) : 311-319.
  • 6Pamonsinlapatham P, Hadj-Slimane R, Lepelletier Y, et al. pl20-Ras GTPase activating protein (RasGAP): a muhi- interacting protein in downstream signaling [ J ]. Biochimie, 2009, 91(3): 320-328.
  • 7Sung H, Kanchi KL, Wang X, et al.Inactivation of RASA1 pro- motes melanoma tumorigenesis via R-Ras activation [ J ]. Oncotar- get,2016,7(17) :23885-23896.
  • 8Liu Y, Liu T, Sun Q, et al. Downregulation of Ras GTPaseacti- vating protein 1 is associated with poor survival of breast invasive duetal carcinoma patients [ J~. Oncol Rep, 2015, 33 ( 1 ) : 119 - 124.
  • 9Zhu YJ, Xu B, Xia W.Hsa-mir-182 downregulates RASA1 and suppresses lung squamous cell carcinoma cell proliferation [ J ]. Clin Lab,2014,60( 1 ) : 155-159.
  • 10Campbell JD, Alexandrov A, Kim J, et al. Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas[ J]. Nat Genet, 2016, 48 (6):607 -616.

引证文献5

二级引证文献16

中国病理生理杂志
2012年 第6期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部